Skip to main content
Home
Issues
Issue Archive
Topics
Conference Correspondent
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
Issue Archive
Topics
Conference Correspondent
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Articles
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Identification of Baseline Characteristics That Predict Good Outcome of alloHCT in Young CLL Patients - A Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Preclinical Analyses Support Clinical Investigation of Combined Anti-CD19 CAR-T Cell, JCAR017 with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Long-Term Follow-Up of Chlorambucil plus Rituximab Combination as Frontline Therapy for Elderly and/or Unfit Patients with CLL, Including Risk Stratification
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Initial Results of a Multicenter, Phase II Study of Ibrutinib plus FCR (iFCR) as Frontline Therapy for Younger CLL Patients
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Outcomes of Ibrutinib Therapy by Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2)
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Updated Safety and Efficacy Data for Ibrutinib as First-Line Treatment in Older Patients with CLL or SLL
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
5-Year Ibrutinib Therapy in Treatment-Naïve Patients with Relapsed or Refractory CLL or SLL
Read More
101
102
103
104
105
106
107
Page 104 of 244
Results 1031 - 1040 of 2439
